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CLINICAL PRESENTATION AND DIAGNOSIS
Renal cell carcinoma is by far the commonest cancer in this group.
Presentation may be with local symptoms. Thus haematuria, usually
painless though sometimes with colicky pain secondary to blood
clots, is common. Less often, a swelling or aching in the loin may be
noticed by the patient. Often and increasingly the tumour is picked
up coincidentally during an imaging investigation (e.g., ultrasound
scan of the abdomen). Metastatic disease may be evident, in up to a
third of patients, as bone, lung or brain secondaries or by systemic
features such as weight loss, fever, malaise and anaemia. Such
features may also be present with organ-confined disease.
TREATMENT
Surgery is the cornerstone of treatment. Nephrectomy is poten-
tially curative for tumours confined to the kidney and/or regional
nodes and is of value in reducing tumour bulk in palliating
advanced disease. With metatastic disease radiotherapy may help
in palliating local symptoms. Conventional chemotherapy has little
value and although immunotherapy with interferon-a or inter-
leukin-2 does marginally improve progression-free and overall
survival, it is at the cost of marked toxicity. However international
efforts continue to develop ways of identifying the small minority of
patients who will benefit greatly from immunotherapy. More recently
knowledge of molecular pathways involved, particularly in clear cell
renal carcinoma, has provided a rationale for targeted treatment.
Agents have been identified, which target gene products, such as
vascular endothelial growth factor (VEGF) and platelet derived
growth factor (PDGF), implicated in tumourigenesis. Such agents
have demonstrated significant activity in clinical trials and represent a
major advance in treatment (Brugarolas, 2007).
INCIDENCE AND SURVIVAL PATTERNS
Only a small number of kidney cancers have an inherited basis, as
for example von Hippel–Lindau (VHL) disease where the cancer
risk for a variety of tumours including renal carcinoma is
transmitted in an autosomal dominant manner. It is now known
that the VHL suppressor gene is mutated or silenced in most clear
cell renal carcinomas though the initiator(s) of this event are still
unknown. Information on risk factors for renal cell carcinoma has
come from a large number of international case control and cohort
studies (McLaughlin et al, 2006). Cigarette smoking and obesity
are the most consistently established causal factors, smoking
having a greater effect in men, obesity possibly in women. It is
important to take these factors into account when interpreting
incidence trends. Across the community obesity is increasing and
smoking decreasing. From the data presented by Westlake et al
(2008), there has been an improvement in relative survival over the
period 1986–1999. Most likely this reflects general improvements
in health care, and possibly earlier diagnosis, rather than in
specific therapies – the 1980s and 1990s were the decades of
biological therapy where early promise of improvements in
survival never came to significant fruition. Deprivation still seems
to be an important factor in prognosis in men, but less so in
women; the reasons for this are unclear. Certainly these trends
cannot be related to known changes in smoking and obesity but
could be linked to changes over time in health care and earlier
diagnosis across the socioeconomic spectrum.
FUTURE CLINICAL IMPLICATIONS
It is disappointing that survival figures for English patients (up to
mid 1990s), were among the lowest in Europe but reassuring that
improvements have particularly been seen during the late 1990s.
All patients now have the benefit of having their case discussed
by a multidisciplinary team including specialist urology and
oncology clinicians, with access to optimal treatments and also
information on clinical trials. For example, a new randomised
study (SORCE) assessing the function of adjuvant sorafenib
(one of the new generation of VEGF inhibitors) in high-risk
resected renal cancer has recently been launched. For metastatic
disease sunitinib and sorafenib (VEGF inhibitors) have now
been licensed in the United Kingdom on the basis of evidence
from large randomised controlled clinical trials (Motzer et al,
2007; Escudier et al, 2007). These agents and others are not
yet generally available in the National Health Service and are
currently being appraised by the National Institute for
Clinical Excellence. There is every hope, therefore, that the
improvements in survival reported in the accompanying article
will continue into and beyond the first decade of the 21st century.
In addition there is considerable interest in prognostic models
(based on clinical and laboratory data) that have been constructed
to provide meaningful risk stratification for clinical trials (Shuch
et al, 2006), the results of which can then be extrapolated to
tumour registry survival data and help in our understanding of the
factors that influence trends and socioeconomic inequalities in
survival.
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